Literature DB >> 2460229

Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes.

C Stähli1, M Caravatti, M Aeschbacher, C Kocyba, B Takacs, H Carmann.   

Abstract

Three monoclonal antibodies [MAb], b-8, b-12, and b-15, have previously been shown to react with mammary carcinomas and with a restricted set of cells in normal human tissues [C. Stähli et al., Experientia (Basel), 41: 1377-1381, 1985; H. R. Zenklusen et al., Virchows Arch. Abt. A Pathol. Anat., 413: 3-10, 1988]. They are shown here to recognize the same high molecular weight acid soluble glycoprotein antigen. Lectin binding, biolabeling, and deglycosylation experiments demonstrate that it contains O-linked carbohydrate side chains with sialic acid and hexoses including fucose, galactose, and/or galactosamine but little if any mannose. These properties, typical of mucin-like glycoproteins, agree with the antigen expression on mucin-secreting epithelial surfaces (H. R. Zenklusen et al., Virchows Arch. Abt. A Pathol. Anat., 413:3-10, 1988). The antigen is thus named mucin-like carcinoma-associated antigen (MCA). The three MAb are shown to bind to three different epitopes on MCA. Two of these epitopes (MCA-b-8 and MCA-b-15) are O-linked carbohydrates, and one (MCA-b-15) contains sialic acid. The epitope MCA-b-12 is of peptide nature. Of various two-site sandwich enzyme immunoassays composed of different combinations of the three MAb, the one with MAb b-12 in both positions is selected for a serum assay. Analyses of tumor patients' sera demonstrate that this MCA enzyme immunoassay can be of use as a tumor marker assay for mammary carcinomas. The parameter MCA enzyme immunoassay is shown to differ from other parameters described in the literature.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460229

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Serological screening for a mucine-like carcinoma-associated antigen (MCA) in patients with gastrointestinal tract malignancies.

Authors:  W Scheithauer; D Mairinger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 2.  Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: elucidation of molecular structure and function.

Authors:  Albert S B Edge
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

3.  Autologous human B-cell immune response to pulmonary adenocarcinomatous polymorphic epithelial mucin.

Authors:  J Xiang; T Moyana; A Maksymiuk
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

4.  Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Authors:  M Stierer; H R Rosen; E Forster; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

Review 5.  Primary duodenal carcinoma arising in a non-vaterian tubulo-villous adenoma. A case report with immunocytochemical analysis and review of the literature.

Authors:  H R Zenklusen; J Landmann; A Feess; M Dürig; M Kasper; M Oberholzer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

6.  The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.

Authors:  P Deprés-Brummer; M Itzhaki; P J Bakker; F J Hoek; K H Veenhof; R de Wit
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.

Authors:  G G Steger; R Mader; K Derfler; K Moser; C Dittrich
Journal:  Klin Wochenschr       Date:  1989-08-17

8.  Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.

Authors:  M Gion; M Plebani; R Mione; C Penzo; S Meo; A Burlina
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

9.  Characterization of OM-B monoclonal antibody-defined antigen associated with mucinous type human ovarian tumor.

Authors:  K Nishida; R Ueda; K Sakakibara; Y Minoura; M Ohta; Y Ariyoshi; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1993-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.